Your AI-Trained Oncology Knowledge Connection!
Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.
Patient concern about coronavirus 2019 varies by oncology clinic according to the OncologyLive® advisory board members, who discussed in a recent interview how COVID-19 has guided their patient interactions and what steps they are advising patients to take to protect themselves.
The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD
The frontline treatment of patients with multiple myeloma continues to evolve with novel, multidrug regimens that are leading to higher, deeper, and more durable responses, as well as increased rates of minimal residual disease negativity.
Benjamin Leon Musher, MD, discusses sequencing challenges and research efforts needed regarding immunotherapy in hepatocellular carcinoma before it becomes a standard approach for patients.
The addition of elotuzumab to lenalidomide and dexamethasone did not show a statistically significant improvement in progression-free survival compared with lenalidomide/dexamethasone alone in patients with newly diagnosed, previously untreated, transplant-ineligible multiple myeloma.
Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.
Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma, according to findings from the phase III POUT trial that have now been published in The Lancet.
Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.
As coronavirus disease 2019 (COVID-19) continues to spread around the world, several oncology-based organizations are taking precautionary measures to protect physicians and patients alike from infection, including making the decision to postpone, or even cancel, select medical conferences.
Madan Jagasia, MBBS, MS, MMHC, discusses the current treatment landscape and next steps in graft-versus-host-disease.
Durvalumab alone did not improve overall survival compared with standard-of-care chemotherapy in patients with unresectable urothelial cancer whose tumors had high levels (≥25%) of PD-L1 expression, missing both primary endpoints of the phase III DANUBE trial.
Larotrectinib continued to show strong tumor-agnostic efficacy in patients with TRK fusion–positive cancers, according to results from an integrated analysis of 3 clinical trials.
The FDA has granted an orphan drug designation to umbralisib for the treatment of patients with follicular lymphoma.
Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.
Bruce G. Raphael, MD, discusses recent pivotal trials in chronic lymphocytic leukemia and the utility of triplet regimens for older patients.
The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab.
Marc J. Braunstein, MD, PhD, expands on the 3- and 4-drug regimens that are showing promise in the multiple myeloma paradigm.
Multiple immune-infiltrate features in the immune-genomic landscape of osteosarcoma, such as poor tumor infiltration by immune cells, low T-cell activity, a lack of immune-stimulating neoantigens, and immune-suppressing pathways, contribute to the limited clinical activity associated with checkpoint inhibitors in this disease, according to results of a study published in Nature Communications.
Robb S. Friedman, MD, examines the developing role of venetoclax in relapsed/refractory multiple myeloma, based on the BELLINI results, and shares his anecdotal experience with the drug in the community setting.
Paul G. Richardson, MD, discusses the findings from the ICARIA-MM trial and the clinical implications of isatuximab’s FDA approval in multiple myeloma.
City of Hope scientists have developed and tested the first CAR T-cell therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells.
Faith E. Davies, MD, discusses pivotal research in relapsed/refractory myeloma and precision medicine efforts in the field.
Michael J. Overman, MD, discusses the current treatment landscape of metastatic colorectal cancer and ongoing research efforts in the space.
Clara D. Bloomfield, MD, the 2015 Giants of Cancer® award winner for Myeloid Neoplasms and a revolutionary physician-scientist, died March 1 at the age of 77.
Michael L. Grossbard, MD, discusses recent changes to the follicular lymphoma paradigm and therapeutic approaches on the horizon.
Patients with breast cancer who are ultrarapid or poor CYP2D6 metabolizers of tamoxifen have a worse prognosis compared with normal metabolizers after receiving a standard dose of the drug, due, in part, to a higher incidence of treatment-related adverse events.
Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in patients with metastatic castration-resistant prostate cancer.
The FDA has granted a breakthrough device designation to the Elecsys GALAD score, an algorithmic score designed to aid in the diagnosis of early-stage hepatocellular carcinoma.
Shella Saint Fleur-Lominy, MD, PhD, discusses some of the current and investigational treatment options for patients with myeloproliferative neoplasms.